24/7 Market News Snapshot 09 October, 2025 – Cabaletta Bio, Inc. Common Stock (NASDAQ:CABA)

October 9, 2025

DENVER, Colo., 09 October, 2025 (www.247marketnews.com) – (NASDAQ:CABA) are discussed in this article.
Cabaletta Bio, Inc. (CABA) is experiencing significant momentum following the initial presentation of promising data from its RESET-PV™ trial, demonstrating the effectiveness of rese-cel (resecabtagene autoleucel) in treating pemphigus vulgaris (PV) without preconditioning. Cheered by investors, the stock opened at $2.40 and surged by 26.1% to reach $3.039, indicating strong market interest and confidence in the company’s innovative therapeutic approach.

During a recent late-breaking oral session at the European Society of Gene & Cell Therapy (ESGCT) Annual Congress, Dr. Samik Basu highlighted key findings from the trial, which involved three refractory patients receiving a single infusion of rese-cel at a dosage of 1 x 10^6 cells/kg. Remarkably, complete B cell depletion was achieved in these patients, along with a rapid drop in autoantibody levels and notable clinical symptom resolution in two of the three subjects. Following the treatment, all participants have remained off immunomodulators and are either tapering off or have completely stopped using corticosteroids.

Dr. David J. Chang, Chief Medical Officer of Cabaletta, expressed enthusiasm over the preliminary findings, stating that these results provide compelling evidence that rese-cel can lead to significant early responses with a simplified treatment regimen, thereby potentially enhancing accessibility for patients seeking alternatives to traditional preconditioning therapies. The trial results indicate that CAR T cell expansion in patients without preconditioning mirrors outcomes seen in earlier RESET trials where preconditioning was utilized.

Cabaletta Bio maintains a strong commitment to advancing targeted cell therapies for autoimmune diseases, with all adult cohorts in its Phase 1/2 RESET trials enrolling patients with myositis, lupus, scleroderma, and myasthenia gravis. The company is well-positioned to further explore rese-cel’s potential applications and will be sharing additional updates on its progress at upcoming medical conferences.

Related news for (CABA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.